medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2013, Número 4

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2013; 29 (4)


Leucemia congénita

Roque-GarcíaI W, Morán-Obregón N, Rodríguez-Acosta M, Gutiérrez-Díaz A

Idioma: Español
Referencias bibliográficas: 34
Paginas:
Archivo PDF: 136.75 Kb.


RESUMEN

La leucemia congénita constituye una entidad rara que se diagnostica entre el momento del nacimiento y los primeros 30 días de vida. Menos del 1 % de las leucemias de la infancia se diagnostican en el neonato. Se caracteriza por la presencia en un recién nacido, de hepatomegalia, esplenomegalia y lesiones hemorrágicas o infiltrativas en piel. El hemograma completo, el examen de la lámina de la sangre periférica, el aspirado de médula ósea, junto con el inmunofenotipaje y los estudios de biología molecular confirmarán el diagnóstico. El trastorno mieloproliferativo transitorio y las infecciones congénitas constituyen los principales diagnósticos diferenciales. El pronóstico de la enfermedad es sombrío. El tratamiento está basado en regímenes de poliquimioterapia intensiva y el trasplante de progenitores hematopoyéticos constituye una opción terapéutica en un grupo de pacientes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al. Leukemia. In: Ries LAG, et al., eds. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. Bethesda, MD: National Cancer Institute, SEER Program NIH Publ, 1999:17–34.

  2. Linet MS, Devesa SS. Epidemiology of leukemia: overview and patterns of occurrence. In: Henderson ES, Lister TA, Greaves MF, eds. Leukemia. Philadelphia: WB Saunders, 2002:131–51.

  3. Ries LAG, Eisner MP, Kosary CL. SEER Cancer statistics review, 1973–1999. Bethesda, MD: National Cancer Institute, 2002.

  4. Vormoor J, Chintagumpala M. Leukaemia and cancer in neonates. Semin Fetal Neonatal Med. 2012 Aug;17(4):183-4.

  5. Bresters D, Reus AC, Veerman AJ, van Wering ER, van der Does-van den Berg A, Kaspers GJ. Congenital leukaemia: the Dutch experience and review of the literature. Br J Haematol. 2002;117:513-24.

  6. Isaacs Jr H. Fetal and neonatal leukemia. J Pediatr Hematol Oncol 2003;25:348-61.

  7. Odom LF. Acute myeloid leukemia in children. In: Hoffman R, Benz EJ, Shattel SJ, eds. Hematology: basic principles and practice. New York: Churchill Livingstone, 1995.

  8. van der Linden MH, Valsecchi MG, De Lorenzo P, Moricke A, Janka G, Leblanc TM, et al. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood. 2009;114:3764-8.

  9. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14:355-68.

  10. Zweidler-McKay PA, Hilden JM. The ABCs of Infant Leukemia. Curr Probl Pediatr Adolesc Health Care. 2008;38:78-94.

  11. Ford AM, Ridge SA, Cabrera ME, et al. In utero rearrangements in the trithorax related oncogene in infant leukaemias. Nature. 1993;363(6427):358-60.

  12. Gale KB, Ford AM, Repp R, et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA. 1997;94:13950-4.

  13. Shu XO, Ross JA, Pendergrass TW, Reaman GH, Lampkin B, Robison LL. Parental alcohol consumption, cigarette smoking, and risk of infant leukemia: a children’s cancer group study. J Natl Cancer Inst. 1996;88:24-31.

  14. Pombo-de-Oliveira MS, Koifman S. Infant acute leukemia and maternal exposures during pregnancy. Cancer Epidemiol Biomarkers Prev. 2006;15:2336-41.

  15. Menegaux F, Steffen C, Bellec S, Baruchel A, Lescoeur B, Leverger G, et al. Maternal coffee and alcohol consumption during pregnancy, parental smoking and risk of childhood acute leukaemia. Cancer Detect Prev. 2005;29:487-93.

  16. Trivers KF, Mertens AC, Ross JA, Steinbuch M, Olshan AF, Robison LL. Parental marijuana use and risk of childhood acute myeloid leukaemia: a report from the Children’s Cancer Group (United States and Canada). Paediatr Perinat Epidemiol. 2006;20:110-8.

  17. Tower RL, Spector LG. The epidemiology of childhood leukemia with a focus on birth weight and diet. Crit Rev Clin Lab Sci. 2007;44(3):203-42.

  18. Ishii E, Oda M, Kinugawa N, et al. Features and outcome of neonatal leukemia in Japan: experience of the Japan infant leukemia study group. Pediatr Blood Cancer. 2006;47:268-72.

  19. van der Linden MH, Creemers S, Pieters R. Diagnosis and management of neonatal leukaemia. Seminars Fetal Neonatal Med. 2012;17:192-5.

  20. Lion T, Haas OA, Harbott J, et al. The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children. Blood. 1992;79:3325–30.

  21. Xavier AC, Taub JW. Acute leukemia in children with Down syndrome. Haematol. 2010 Jul;95(7):1043-45.

  22. Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM, Sandoval C. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood. 2007;110:2128-31.

  23. Bajwa RP, Skinner R, Windebank KP, Reid MM. Demographic study of leukaemia presenting within the first 3 months of life in the Northern Health Region of England. J Clin Pathol. 2004;57:186-8.

  24. Roy A, Roberts I, Vyas P. Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome. Seminars Fetal Neonatal Med. 2012;17:196-01.

  25. Dinulos JG, Hawkins DS, Clark BS, Francis JS. Spontaneous remission of congenital leukemia. J Pediatr. 1997;131:300-3.

  26. Massey GV, Zipursky A, Chang MN,Doyle JJ, Nasim S, TaubJW, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS):children’s Oncology Group (COG) study POG-9481. Blood. 2006;107:4606-13.

  27. Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, Sharma M, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates:a report from the Children’s Oncology Group Study A2971. Blood. 2011 Dec 22 ;118(26) :6752-9.

  28. Sande JE, Arceci RJ, Lampkin BC. Congenital and neonatal leukemia. Semin Perinatol. 1999;23:274-85.

  29. Veal GJ, Boddy AV. Chemotherapy in newborns and preterm babies. Seminars Fetal Neonatal Med. 2012 Aug; 17(4):243-8.

  30. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Kremens B, Lehrnbecher T, et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia. 2012 Apr;26(4):654-61.

  31. O Brien MM, Lacayo NJ. Acute leukemia in children. Conn´s Current Ther. 2008;6:446-53.

  32. Interfant 99: International collaborative treatment protocol for infants under one year with acute lymphoblastic leukaemia. Clinical Trial. NCT00015873. Disponible en: http://ichgcp.net/clinical-trials-registry/research/index/NCT00015873

  33. Klusmann JH, Reinhardt D, Zimmermann M, Kremens B, Vormoor J, Dworzak M, et al. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica. 2012 Jan;97(1):21-9.

  34. Dreyer ZE, Dinndorf PA, Camitta B, Sather H, LA MK, Devidas M, et al. Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the children’s oncology group. J Clin Oncol. 2011 Jan;29(2):214-22.




2020     |     www.medigraphic.com